Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival. | Leukemia | 2026 | 42827117 | PubTator, text mining | PubMed |
| Venetoclax consolidation deepens response and enables measurable residual disease-guided finite therapy in BTK inhibitor-treated chronic lymphocytic leukemia. | Leuk Lymphoma | 2026 | 42822838 | PubTator, text mining | PubMed |
| Acquired Amegakaryocytic Thrombocytopenia Presenting as Pancytopenia in a Patient With Chronic Lymphocytic Leukemia: A Case Report. | Case Rep Hematol | 2026 | 42761550 | PubTator, text mining | PubMed |
| A specific molecular profiling of secreted rheumatoid factors in Sjögren's disease patients with lymphoma. | Rheumatology (Oxford) | 2026 | 42750166 | PubTator, text mining | PubMed |
| RNA sequencing detects more challenging cases of somatic hypermutation in the IgHV gene in patients with chronic lymphocytic leukemia. | Turk J Med Sci | 2026 | 42677266 | PubTator, text mining | PubMed |
| Consensus-based ranking of determinants for frontline therapy selection in chronic lymphocytic leukemia: A conjoint analysis. | Crit Rev Oncol Hematol | 2026 | 42633864 | PubTator, text mining | PubMed |
| Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial). | J Natl Cancer Cent | 2026 | 42630801 | PubTator, text mining | PubMed |
| Venetoclax in Combination With Chemo-Immunotherapy in Richter Transformation: A Real-Life Experience. | Hematol Oncol | 2026 | 42607055 | PubTator, text mining | PubMed |
| Dysregulated BCR repertoire and metabolic state of HBsAg-specific B cells in chronic hepatitis B revealed by integrated single-cell analysis. | Hepatol Commun | 2026 | 42579769 | PubTator, text mining | PubMed |
| Chronic lymphocytic leukemia management in India: balancing evidence, access, and affordability in clinical practice. | Front Oncol | 2026 | 42528663 | PubTator, text mining | PubMed |
| Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia. | Blood Adv | 2026 | 42498281 | PubTator, text mining | PubMed |
| Molecular Pathogenesis and Therapeutic Response of Diffuse Large B Cell Lymphoma Genetic Subtypes. | Annu Rev Cancer Biol | 2026 | 42487683 | PubTator, text mining | PubMed |
| Molecular-level analysis of serum IgG repertoires in COVID-19-vaccinated people with cystic fibrosis identifies abundant convergent antibodies. | bioRxiv | 2026 | 42465256 | PubTator, text mining | PubMed |
| Rare CNS manifestation of high-risk CLL with excellent response to triplet targeted therapy. | Leuk Res Rep | 2026 | 42440393 | PubTator, text mining | PubMed |
| The prognostic implications of autoimmune hemolytic anemia in chronic lymphocytic leukemia across treatment eras. | Haematologica | 2026 | 42389827 | PubTator, text mining | PubMed |
| GWAS analysis of a depression cohort defined by an EHR-phenotyping algorithm reveals the role of immune regulations in depression risk. | Front Genet | 2026 | 42382129 | PubTator, text mining | PubMed |
| Focal adhesion kinase FAK interplays with ROR1 in the aggressiveness of chronic lymphocytic leukemia. | BMC Med | 2026 | 42374527 | PubTator, text mining | PubMed |
| Single-cell profiling of immune activation, dysregulation, and reconstitution in rhesus macaques after measles virus infection. | J Immunol | 2026 | 42343163 | PubTator, text mining | PubMed |
| Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial. | Blood | 2026 | 42322115 | PubTator, text mining | PubMed |
| Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center Study. | Hematol Oncol | 2026 | 42241337 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers